Preview

User

Not a user? Register with this site Forgot your password?

Nephrology and Dialysis

Advanced search

Executive summary of the KDIGO 2021 guidelinefor the management of glomerular diseases

https://doi.org/10.28996/2618-9801-2022-1-21-51

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (GN), both adults and children. The scope includes various glomerular diseases, including IgA nephropathy and IgA vasculitis, membranous nephropathy, nephrotic syndrome, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), infection-related GN, antineutrophil cytoplasmic antibody (ANCA) vasculitis, lupus nephritis, and anti-glomerular basement membrane antibody GN. In addition, this guideline will be the first to address the subtype of complement-mediated diseases. Each chapter follows the same format providing guidance related to diagnosis, prognosis, treatment, and special situations. The goal of the guideline is to generate a useful resource for clinicians and patients by providing actionable recommendations based on evidence syntheses, with useful infographics incorporating views from experts in the field. Another aim is to propose research recommendations for areas where there are gaps in knowledge. The guideline targets a broad global audience of clinicians treating GN while being mindful of implications for policy and cost. Development of this guideline update followed an explicit process whereby treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach. Limitations of the evidence are discussed, with areas of future research also presented.

About the Authors

Brad H. Rovin
The Ohio State University College of Medicine
Russian Federation


Sharon G. Adler
Los Angeles Biomedical Research Institute
Russian Federation


Jonathan Barratt
University of Leicester
Russian Federation


Frank Bridoux
University Hospital Poitiers
Russian Federation


Kelly A. Burdge
Mass General Brigham-Salem Hospital
Russian Federation


Tak Mao Chan
University of Hong Kong
Russian Federation


H. Terence Cook
Imperial College London
Russian Federation


Fernando C. Fervenza
Mayo Clinic
Russian Federation


Keisha L. Gibson
University of North Carolina Kidney Center at Chapel Hill
Russian Federation


Richard J. Glassock
University of California
Russian Federation


David R.W. Jayne
University of Cambridge
Russian Federation


Vivekanand Jha
The George Institute for Global Health; Imperial College London; Manipal Academy of Higher Education
Russian Federation


Adrian Liew
Mount Elizabeth Novena Hospital
Russian Federation


Zhi-Hong Liu
Nanjing University School of Medicine
Russian Federation


Juan M. Mejía-Vilet
Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran
Russian Federation


Carla M. Nester
University of Iowa
Russian Federation


Jai Radhakrishnan
Columbia University
Russian Federation


Elizabeth M. Rave
Ohio Kidney Associates
Russian Federation


Heather N. Reich
University of Toronto
Russian Federation


Pierre Ronco
Sorbonne University, and Institut National de la Santé et de la Recherche Médicale; Le Mans Hospital
Russian Federation


Jan-Stephan F. Sanders
University of Groningen
Russian Federation


Sanjeev Sethi
Mayo Clinic
Russian Federation


Yusuke Suzuki
Juntendo University
Russian Federation


Sydney C.W. Tang
University of Hong Kong
Russian Federation


Vladimír Tesar
Charles University
Russian Federation


Marina Vivarelli
Ospedale Pediatrico Bambino Gesù
Russian Federation


Jack F.M. Wetzels
Radboud University
Russian Federation


Lyubov Lytvyn
MAGIC Evidence Ecosystem Foundation; McMaster University
Russian Federation


Jonathan C. Craig
Flinders University; Cochrane Kidney and Transplant
Russian Federation


David J. Tunnicliffe
The University of Sydney; Cochrane Kidney and Transplant
Russian Federation


Martin Howell
The University of Sydney; Cochrane Kidney and Transplant
Russian Federation


Marcello A. Tonelli
University of Calgary
Russian Federation


Michael Cheung
KDIGO
Russian Federation


Amy Earley
KDIGO
Russian Federation


Jürgen Floege
Rheinisch-Westfälische Technische Hochschule (RWTH)
Russian Federation


Review

For citations:

Rovin B.H., Adler Sh.G., Barratt J., Bridoux F., Burdge K.A., Chan T.M., Cook H.T., Fervenza F.C., Gibson K.L., Glassock R.J., Jayne D.R., Jha V., Liew A., Liu Zh., Mejía-Vilet J.M., Nester C.M., Radhakrishnan J., Rave E.M., Reich H.N., Ronco P., Sanders J.F., Sethi S., Suzuki Yu., Tang S.C., Tesar V., Vivarelli M., Wetzels J.F., Lytvyn L., Craig J.C., Tunnicliffe D.J., Howell M., Tonelli M.A., Cheung M., Earley A., Floege J. Executive summary of the KDIGO 2021 guidelinefor the management of glomerular diseases. Nephrology and Dialysis. 2022;24(1):21-51. (In Russ.) https://doi.org/10.28996/2618-9801-2022-1-21-51

Views: 179


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1680-4422 (Print)
ISSN 2618-9801 (Online)

123182, Moscow, Pekhotnaya str., 3
e-mail: nephro-dial@yandex.ru

Processing of personal data
supported by NEICON (Elpub lab)